Greenwich LifeSciences (GLSI) Free Cash Flow (2019 - 2025)
Greenwich LifeSciences (GLSI) posted Free Cash Flow of -$3.2 million for Q4 2025, down 18.85% on a QoQ basis from -$2.7 million in Q3 2025, and down 71.4% year-over-year from -$11.1 million in Q4 2024.
Greenwich LifeSciences (GLSI) Free Cash Flow (2019 - 2025) Analysis & Trends
Greenwich LifeSciences' Free Cash Flow history runs 6 years deep, the most recent figure standing at -$3.2 million for Q4 2025.
- Quarterly Free Cash Flow fell 71.4% year-over-year to -$3.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$9.9 million (down 36.43% YoY) and the FY2025 annual result came in at -$9.9 million, down 36.43% from the prior year.
- Free Cash Flow was -$3.2 million for Q4 2025 at Greenwich LifeSciences, down from -$2.7 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$528270.0 in Q1 2021 and bottomed at -$3.2 million in Q4 2025.
- A 5-year average of -$1.7 million and a median of -$1.8 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 268.65% — and 2023, when it grew 20.06%.
- Greenwich LifeSciences' Free Cash Flow stood at -$2.3 million in 2021, then climbed by 4.16% to -$2.2 million in 2022, then climbed by 0.73% to -$2.2 million in 2023, then rose by 14.02% to -$1.9 million in 2024, then tumbled by 71.4% to -$3.2 million in 2025.
- Business Quant data shows GLSI's Free Cash Flow at -$3.2 million in Q4 2025, -$2.7 million in Q3 2025, and -$2.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Greenwich LifeSciences | 178.53 Mn | 178.53 Mn | - | -3.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.17 Mn |
| Dec 31, 2025 | -3.17 Mn |
| Sep 30, 2025 | -2.67 Mn |
| Sep 30, 2025 | -2.67 Mn |
| Jun 30, 2025 | -2.23 Mn |
| Jun 30, 2025 | -2.23 Mn |
| Mar 31, 2025 | -1.83 Mn |
| Mar 31, 2025 | -1.83 Mn |
| Dec 31, 2024 | -1.85 Mn |
| Dec 31, 2024 | -1.85 Mn |
| Sep 30, 2024 | -2.58 Mn |
| Sep 30, 2024 | -2.58 Mn |
| Jun 30, 2024 | -1.05 Mn |
| Jun 30, 2024 | -1.05 Mn |
| Mar 31, 2024 | -1.78 Mn |
| Mar 31, 2024 | -1.78 Mn |
| Dec 31, 2023 | -2.15 Mn |
| Dec 31, 2023 | -2.15 Mn |
| Sep 30, 2023 | -1.80 Mn |
| Sep 30, 2023 | -1.80 Mn |